ISSN: 1083-7159
Journal Home
Journal Guideline
Oncologist Q1 Unclaimed
Oncologist is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 172. It has a price of 1260 €. It has an SJR impact factor of 1.813 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1.813.
Oncologist focuses its scope in these topics and keywords: cancer, patients, metastatic, colorectal, treatment, weeks, cell, therapy, review, agency, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
1260 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1.813
SJR Impact factor172
H Index464
Total Docs (Last Year)1106
Total Docs (3 years)13875
Total Refs5949
Total Cites (3 years)946
Citable Docs (3 years)5.09
Cites/Doc (2 years)29.9
Ref/DocOther journals with similar parameters
Journal of Clinical Oncology Q1
Annals of Oncology Q1
Annual Review of Public Health Q1
The Lancet Global Health Q1
Nature Reviews Disease Primers Q1
Compare this journals
Aims and Scope
Best articles by citations
Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion
View moreThe Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer
View moreEstimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.
View moreTELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World
View moreSurvival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities
View moreFDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
View moreFDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
View moreMultidisciplinary Management of Breast Cancer During Pregnancy
View moreFDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer
View moreUse of High-Cost Cancer Treatments in Academic and Nonacademic Practice
View moreVenous Thromboembolism in Patients with Sarcoma: A Retrospective Study
View moreDiagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor
View moreClinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory
View moreActive Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials
View moreStaging of Regional Nodes in AJCC Stage I and II Melanoma:
View moreBreast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya
View moreA Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
View moreAdvance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study
View moreManaging Vesicant Extravasations
View morePurine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
View moreSafety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens
View moreThe CAIRO and FOCUS Studies: Which Lesson Is to Be Learned?
View moreThe Goal of Cancer Treatment
View moreSrc Inhibition Is Still a Relevant Target in Pancreatic Cancer
View more
Comments